// App-Quantinova.ai

312 : Dose-dependent Suppression of T Cell-Dependent Antibody Response in Healthy Volunteers by KPL-404, an Anti-CD40 Monoclonal Antibody, Supports Phase 2 Study in Patients with Rheumatoid Arthritis

Researchers

Presenter

  • Lara Pupim

Principal Investigators

  • Gerd Burmester

  • Fang Fang

  • Alan Kivitz

  • Moses Njenga

  • Costantino Pitzalis

  • Jay Chatfield

  • Anastassia Papandrikopoulou

  • Manoj Samant

  • Steve Schmitz

  • Madeline Spiers

  • Eben Tessari

  • John Ziemniak

  • John F. Paolini

Medical Centers

  • Kiniksa, Lexington, MA

  • Charite-University Medicine Berlin, Berlin, Germany

  • Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, United States

  • Queen Mary University of London, London, United Kingdom

  • Syndax Pharmaceuticals, Lexington, MA

Locations

  • United States

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved